AF
LXRX icon

Allworth Financial’s Lexicon Pharmaceuticals LXRX Stock Holding History

Allworth Financial’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$632 Buy
+263
New +$512 ﹤0.01% 4803

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allworth Financial's LXRX Position: Q2 2026 in Review

Allworth Financial opened a new position in Lexicon Pharmaceuticals (LXRX) in Q2 2026: 263 shares worth $632. The stake represents ﹤0.01% of the portfolio and ranks #4803 among its holdings.

149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Allworth Financial held 263 shares of Lexicon Pharmaceuticals worth $632 as of Q2 2026.
  • Lexicon Pharmaceuticals was a new Allworth Financial position in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4803 holding.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.